Aethlon Medical Launches Investor Relations Department; Names Tanya Blackshaw Director of Investor Relations.

Business Editors/Health & Medical Writers

SAN DIEGO--(BW HealthWire)--July 12, 2000

Aethlon Medical Inc., (OTCBB:AEMD) announced today that it has established an in-house Investor Relations Department and has named Tanya Blackshaw as director of Investor Relations.

Prior to joining Aethlon Medical, Blackshaw was an investor relations executive at Biosite Diagnostics Inc.

Regarding this development, James A. Joyce, chairman of Aethlon Medical stated, "Since establishing ourselves as a public company, we have successfully increased the applications of our Hemopurifier technology through strategic acquisitions and exclusive license agreements. We will now utilize our Investor Relations Department to communicate the value of these efforts to the financial community." Regarding the addition of Blackshaw, Joyce added, "We are most fortunate to have an individual with Tanya's experience and expertise leading these efforts."

About Aethlon Medical

Aethlon Medical is a leading developer of extracorporeal treatment technologies. Utilizing a proprietary platform technology known as the Hemopurifier(TM), the company has developed an extensive pipeline of disposable products that effectively remove targeted toxins from the blood without side effects. The initial products to be commercialized have been developed to reduce the levels of harmful metal intoxicants and certain toxic chemotherapy agents in the body.

The product line includes Hemopurifiers that treat Iron Overload, Lead Poisoning, and a Chemopurifier that reduces the toxicity associated with Cisplatin based chemotherapy for cancer patients. Products in development include Hemopurifiers to treat virus such as HIV-AIDS and Hepatitis-C. For more information on recent developments at the company, visit the Aethlon Medical Web site at www.aethlonmedical.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical Inc. (the "company"), or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

Readers of this press release may obtain additional information on the company in reports and other information filed in accordance with the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Such reports and other information filed by the company can be inspected and copied at the public reference facilities maintained by the Commission at the Public Reference Room, 450 Fifth Street, N.W., Washington, DC 20549.

Copies of such material can also be obtained at prescribed rates from the Public Reference Section of the Commission, Washington, DC 20549 or by calling the Commission at 800/SEC-0330. In addition, Registration Statements and other filings made with the Commission through its Electronic Data Gathering Analysis and Retrieval System ("EDGAR") and publicly available through the Commission's Web site located at http://www.sec.gov.